...endometrial and breast cancers. Arno held exclusive, worldwide rights to develop and commercialize onapristone from Invivis Pharmaceuticals Inc....

...company Context Therapeutics (Philadelphia, Pa.) named Erard Gilles CMO. He was founder and CMO at Invivis Pharmaceuticals Inc....

...a 2012 deal (see BioCentury, Feb. 20, 2012 ). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
...recommended Phase II dose; safety and pharmacokinetics Status: Phase II halted Milestone: NA Julian Zhu onapristone Arno Therapeutics Inc. Invivis Pharmaceuticals Inc. Progestin...

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....

...under a license from BTG plc (LSE:BTG, London, U.K.). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....